ArticleClinical and translational radiation oncology2026
MR-guided stereotactic radiosurgery of an intracardiac tumoral thrombus using comprehensive motion management.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is often complicated by hypercoagulability, with intracardiac thrombi not an uncommon consequence. While radiotherapy can be a treatment option, effective intracardiac irradiation can be technically challenging. We present the case of a 54-year-old non-small-cell lung cancer (NSCLC) patient treated for a recurrent left atrial tumoral thrombus. The patient responded well after a first course of chemo-immuno radiotherapy. Follow up imaging showed a metabolic reactivation of the left atrial thrombus. The patient subsequently underwent an 18 Gy stereotactic radiosurgery using a 1.5 T Unity MR-Linac (Elekta AB, Sweden, Stockholm) using comprehensive motion management (CMM) to account for respiratory motion. Treatment was well tolerated. Complete metabolic response was observed 2 months after treatment. This case represents the first ever reported use of CMM on a 1.5 T MR-Linac to target an intracardiac lesion.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.